1. Is early antithrombotic therapy necessary in patients with bioprosthetic aortic valves in normal sinus rhythm?
- Author
-
ElBardissi, Andrew W., DiBardino, Daniel J., Chen, Frederick Y., Yamashita, Michael H., and Cohn, Lawrence H.
- Subjects
Salicylates ,Aspirin ,Anticoagulants (Medicine) ,Health - Abstract
To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.jtcvs.2009.10.064 Byline: Andrew W. ElBardissi, Daniel J. DiBardino, Frederick Y. Chen, Michael H. Yamashita, Lawrence H. Cohn Abbreviations: ASA, acetylsalicylic acid; BPAV, bioprosthetic aortic valve; CVA, cerebrovascular accident; NYHA, New York Heart Association; PPM, prosthesis-patient mismatch; TE, thromboembolism; TIA, transient ischemic attack; VKA, vitamin K antagonist Abstract: Current American Heart Association/American College of Cardiology guidelines recommend anticoagulation and antiplatelet therapy during the first 90 postoperative days; however, there is wide variability in the administration of antithrombotic therapy after bioprosthetic aortic valve replacement. We sought to determine whether early antithrombotic therapy was necessary in patients undergoing isolated bioprosthetic aortic valve implantation and who were discharged in normal sinus rhythm. Author Affiliation: Division of Cardiac Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass Article History: Received 25 June 2009; Revised 7 September 2009; Accepted 1 October 2009 Article Note: (footnote) Disclosures: None.
- Published
- 2010